Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALNY |
---|---|---|
09:32 ET | 9631 | 235.49 |
09:34 ET | 600 | 235.14 |
09:36 ET | 1300 | 235.895 |
09:38 ET | 1466 | 238.38 |
09:39 ET | 700 | 238.155 |
09:41 ET | 1500 | 237.63 |
09:43 ET | 800 | 238.23 |
09:45 ET | 907 | 238.28 |
09:48 ET | 1566 | 238.59 |
09:50 ET | 500 | 239.1 |
09:52 ET | 1285 | 240.31 |
09:54 ET | 1327 | 239.75 |
09:56 ET | 500 | 238.755 |
09:57 ET | 300 | 238.82 |
09:59 ET | 500 | 238.285 |
10:01 ET | 300 | 239.56 |
10:03 ET | 500 | 239.25 |
10:06 ET | 900 | 239.45 |
10:08 ET | 1203 | 238.66 |
10:10 ET | 2962 | 237.83 |
10:12 ET | 100 | 237.73 |
10:14 ET | 300 | 237.2 |
10:15 ET | 400 | 237.5 |
10:17 ET | 200 | 237.25 |
10:19 ET | 200 | 237.14 |
10:21 ET | 1604 | 236.4173 |
10:24 ET | 100 | 236.23 |
10:28 ET | 100 | 235.85 |
10:30 ET | 100 | 235.95 |
10:32 ET | 1100 | 235.99 |
10:33 ET | 800 | 236.345 |
10:35 ET | 400 | 236.22 |
10:37 ET | 860 | 236.215 |
10:39 ET | 800 | 236.36 |
10:42 ET | 600 | 236.42 |
10:44 ET | 700 | 235.94 |
10:46 ET | 600 | 235.61 |
10:48 ET | 100 | 235.43 |
10:50 ET | 1258 | 235.365 |
10:51 ET | 825 | 235.03 |
10:53 ET | 300 | 235.21 |
10:55 ET | 600 | 235.16 |
10:57 ET | 1939 | 236.36 |
11:00 ET | 526 | 236.14 |
11:02 ET | 353 | 235.92 |
11:04 ET | 504 | 235.81 |
11:06 ET | 509 | 235.691 |
11:08 ET | 1000 | 235.26 |
11:09 ET | 1776 | 235.38 |
11:11 ET | 1737 | 235.465 |
11:15 ET | 300 | 235.4648 |
11:18 ET | 400 | 235.28 |
11:20 ET | 3203 | 235.46 |
11:22 ET | 100 | 235.405 |
11:24 ET | 2433 | 235.35 |
11:26 ET | 200 | 235.2048 |
11:27 ET | 100 | 235.42 |
11:29 ET | 400 | 235.31 |
11:31 ET | 4576 | 235.69 |
11:33 ET | 100 | 235.76 |
11:36 ET | 100 | 235.78 |
11:38 ET | 467 | 236.075 |
11:40 ET | 2894 | 235.97 |
11:42 ET | 100 | 235.865 |
11:44 ET | 200 | 235.39 |
11:45 ET | 1239 | 235.435 |
11:47 ET | 200 | 235.275 |
11:49 ET | 200 | 235.25 |
11:51 ET | 300 | 234.95 |
11:54 ET | 100 | 235 |
11:56 ET | 900 | 235.03 |
11:58 ET | 200 | 235.165 |
12:00 ET | 414 | 235 |
12:02 ET | 200 | 235 |
12:03 ET | 100 | 235.21 |
12:05 ET | 912 | 235.295 |
12:09 ET | 410 | 235.255 |
12:12 ET | 500 | 235.015 |
12:14 ET | 41949 | 235.31 |
12:16 ET | 497 | 235.245 |
12:18 ET | 900 | 235.295 |
12:20 ET | 449 | 235.34 |
12:21 ET | 1018 | 235.075 |
12:23 ET | 100 | 234.98 |
12:25 ET | 448 | 235 |
12:27 ET | 224 | 235 |
12:30 ET | 4831 | 235.32 |
12:34 ET | 690 | 234.95 |
12:36 ET | 1224 | 234.955 |
12:38 ET | 600 | 234.98 |
12:39 ET | 500 | 235 |
12:43 ET | 400 | 235.31 |
12:45 ET | 100 | 235.13 |
12:48 ET | 305 | 235 |
12:50 ET | 977 | 235 |
12:52 ET | 480 | 235.2 |
12:54 ET | 480 | 235 |
12:56 ET | 714 | 235 |
12:57 ET | 378 | 235 |
12:59 ET | 598 | 235 |
01:01 ET | 300 | 235 |
01:03 ET | 1996 | 235.03 |
01:06 ET | 2719 | 234.99 |
01:08 ET | 3489 | 235.025 |
01:12 ET | 1148 | 234.92 |
01:14 ET | 2348 | 233.875 |
01:15 ET | 200 | 233.88 |
01:17 ET | 1397 | 234.43 |
01:21 ET | 300 | 234.28 |
01:24 ET | 705 | 233.93 |
01:26 ET | 400 | 233.85 |
01:28 ET | 200 | 233.85 |
01:30 ET | 843 | 233.9 |
01:32 ET | 100 | 233.9 |
01:33 ET | 1376 | 233.82 |
01:35 ET | 824 | 233.69 |
01:37 ET | 1527 | 233.955 |
01:42 ET | 500 | 233.97 |
01:44 ET | 100 | 234.095 |
01:46 ET | 734 | 234.33 |
01:48 ET | 300 | 234.48 |
01:50 ET | 100 | 234.485 |
01:51 ET | 700 | 234.35 |
01:53 ET | 120 | 234.355 |
01:55 ET | 1700 | 234.705 |
01:57 ET | 106 | 234.43 |
02:00 ET | 107 | 234.43 |
02:02 ET | 100 | 234.44 |
02:04 ET | 300 | 234.85 |
02:06 ET | 709 | 234.685 |
02:08 ET | 200 | 234.69 |
02:11 ET | 250 | 234.7 |
02:13 ET | 154 | 234.7 |
02:15 ET | 224 | 234.75 |
02:18 ET | 1534 | 234.78 |
02:20 ET | 327 | 234.52 |
02:22 ET | 437 | 234.36 |
02:24 ET | 159 | 234.37 |
02:26 ET | 514 | 234.76 |
02:27 ET | 399 | 234.91 |
02:29 ET | 396 | 234.705 |
02:31 ET | 489 | 234.8 |
02:33 ET | 239 | 234.705 |
02:36 ET | 200 | 234.7 |
02:38 ET | 1666 | 234.91 |
02:40 ET | 223 | 234.75 |
02:42 ET | 1460 | 234.6 |
02:44 ET | 123 | 234.45 |
02:45 ET | 400 | 234.8 |
02:49 ET | 200 | 234.67 |
02:51 ET | 529 | 234.645 |
02:54 ET | 200 | 234.51 |
02:56 ET | 100 | 234.49 |
03:00 ET | 434 | 234.77 |
03:02 ET | 207 | 234.54 |
03:03 ET | 500 | 234.74 |
03:05 ET | 1762 | 234.28 |
03:07 ET | 500 | 234.08 |
03:09 ET | 600 | 234.46 |
03:12 ET | 200 | 234.56 |
03:14 ET | 700 | 234.56 |
03:16 ET | 500 | 234.62 |
03:18 ET | 169 | 234.5734 |
03:20 ET | 400 | 234.53 |
03:21 ET | 500 | 234.68 |
03:23 ET | 1300 | 235.085 |
03:25 ET | 600 | 235.22 |
03:30 ET | 100 | 235.275 |
03:32 ET | 600 | 235.315 |
03:34 ET | 524 | 235.3 |
03:36 ET | 624 | 235.35 |
03:38 ET | 200 | 235.38 |
03:39 ET | 1103 | 235.71 |
03:41 ET | 100 | 235.77 |
03:43 ET | 1253 | 235.72 |
03:45 ET | 300 | 235.76 |
03:50 ET | 3481 | 234.955 |
03:52 ET | 2229 | 235.55 |
03:54 ET | 1926 | 235.45 |
03:56 ET | 12469 | 235.21 |
03:57 ET | 3169 | 235.26 |
03:59 ET | 87014 | 234.84 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Alnylam Pharmaceuticals Inc | 30.1B | -86.7x | --- |
argenx SE | 28.8B | -142.1x | --- |
Neurocrine Biosciences Inc | 14.7B | 40.3x | +62.04% |
Beigene Ltd | 17.4B | -21.5x | --- |
Biomarin Pharmaceutical Inc | 16.3B | 79.0x | --- |
United Therapeutics Corp | 14.9B | 16.0x | +8.22% |
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $30.1B |
---|---|
Revenue (TTM) | $2.0B |
Shares Outstanding | 126.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.38 |
EPS | $-2.71 |
Book Value | $-1.75 |
P/E Ratio | -86.7x |
Price/Sales (TTM) | 15.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -8.78% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.